QCDx

QCDx is a private U.S. medical device and cancer diagnostics company developing liquid-biopsy tools to detect, image, profile, and isolate rare circulating tumor cells from blood for precision oncology. Its core platform combines the RareScope 3D optical tomography system with MultiFluor multiplex immunofluorescent probes to analyze intact and live cells without enrichment, supporting biomarker profiling and potential treatment optimization. The company positions its technology for cancer diagnostics, clinical research, and pharmaceutical drug-development applications. QCDx has highlighted work in breast cancer through the CLINBREAC clinical study and has presented data at oncology conferences. The business appears to be platform-centric rather than a traditional therapeutics developer, with products spanning instruments, consumables, and reagents.